VG Life Sciences Inc. (VGLS)

[ALLEYCATINHEET]

Drug combination indicates more effective solid tumor cancer treatment Furthermore, VGLS has one drug research program in clinical stage, which is a MDT therapy that helps in combination with other drugs to fight cancers with solid tumors in situations where the cancer is resistant to the initial cancer drug therapy. The MDT trial in partnership with the University of Texas at San Antonio is intended to explore the possibility to combine VGL`s drug with Sorafenib, which has been co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar. Nexavar is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer and radioactive iodine resistant advanced thyroid carcinoma. Nexavar has been extremely succesfull in treating the intended conditions and is currently generating approximately $1.5 Billion in annual sales. The patent for the drug is expiring in 2017.

Read more: http://stockreads.com/Stock-Newsletter.aspx?id=83993#ixzz4qfKUj08d